Abstract
Objective To study the argon laser treating choroidal neovascularization(CNV)of macular area by the way similar to transpupilary thermotherapy,and to observe its therapeutic effect and safety.Methods Fifty-five cases(59 eyes)diagnosed as CNV of macular area and treated with argon laser therapy were collected in our Department of Ophthalmology for 2 years.The changes of the best corrected visual acuity(BCVA),fluorescence fundus angiography(FFA)and Optical Coherence Tomography(OCT),the complication and the recurrence rate were observed pre and post treatment.And the results were analyzed by the method of statistics.Results All patients were treated with argon laser(83.05% was treated 1 time,16.95% was treated 2 times).The postoperative follow-up of 6 to 20 months revealed that the BCVA improved in 21 eyes(35.59%),remained unaltered in 35 eyes(59.32%)and diminished in 3 eyes(5.08%).FFA,OCT showed that CNV atrophy,exudative detachment of retina,hemorrhagic retinal pigment epithelium detachment and macular edema resolution,but blindspot not affected vision occurred in 2 eyes(3.39%)without the other complication appeared.Conclusions Argon laser therapy treated CNV of macular area is safe and effective,which makes CNV atrophy,blood vessel atresia in bleeding part,further intraretina fluid and haematocele and subretinal fluid absorption.Patient's vision is improved and conserved,and it is economy and accepted generally. Key words: Argon laser; Choroidal neovascularization(CNV)of macular area
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.